Clarithromycin

This product belongs to the 14-membered macrolide antibiotics. The antibacterial spectrum is the same as that of erythromycin and roxithromycin, but it is slightly better against Gram-positive bacteria such as Streptococcus, Pneumococcus, and Staphylococcus, and it also has certain antibacterial activity against induced erythromycin-resistant strains. Clarithromycin and its metabolites in the body enhance the antibacterial effect on influenza bacilli. This product also has a certain effect on gonococci, Listeria, and Campylobacter jejuni, and has a stronger effect on Legionella pneumophila, Mycoplasma pneumoniae, Chlamydia trachomatis, Ureaplasma urealyticum, etc. than erythromycin. It has a more prominent effect among the new varieties developed in recent years, with MIC90 of about 0.008-0.12 mg/L. In addition, it has a certain activity against Borrelia burgdorferi, Mycobacterium avium, Toxoplasma gondii, etc., and most of them are better than other varieties. In addition to having a strong antibacterial effect on anaerobic cocci, its effect on Bacteroides fragilis is better than erythromycin, etc. The post-antibiotic effect of this product on Staphylococcus aureus, Streptococcus pyogenes, Haemophilus influenzae, etc. is significantly stronger than erythromycin. This drug belongs to the macrolide antibiotics, and its mechanism is to inhibit the synthesis of proteins by hindering the association of the 50S subunit of the nucleoprotein. This drug has an inhibitory effect on Gram-positive bacteria such as Staphylococcus aureus, Streptococcus, and Pneumococcus, and also has an inhibitory effect on some Gram-negative bacteria such as Haemophilus influenzae, Bordetella pertussis, Gonorrhea, Legionella pneumophila, and some anaerobic bacteria such as Bacteroides fragilis, Streptococcus, and Propionibacterium acnes. In addition, it also has an inhibitory effect on mycoplasma. The characteristics of this drug are that its antibacterial activity in vitro is similar to that of erythromycin, but its antibacterial activity in vivo against some bacteria such as Staphylococcus aureus, Streptococcus, and Haemophilus influenzae is stronger than erythromycin. There is cross-resistance between it and erythromycin.

Clarithromycin

This drug is mainly used for upper and lower respiratory tract infections caused by sensitive bacteria, including tonsillitis, pharyngitis, sinusitis, bronchitis pneumonia, skin and soft tissue infections, furuncle, erysipelas, folliculitis, wound infections, etc. Its efficacy is similar to that of other macrolides. This drug can also be used for genital and urinary tract infections caused by Chlamydia trachomatis or Ureaplasma urealyticum, and atypical mycobacterial infections in AIDS patients.

Adults take 250 mg every 12 hours, and the dose for severe patients can be increased to 500 mg every 12 hours; the course of treatment depends on the severity of the infection, generally 7 to 14 days. The dose is halved for patients with creatinine clearance lower than 0.501 ml/1.73 m2·sec. Children's dose: 7.5 mg/kg each time, twice a day, and the maximum dose does not exceed 500 mg per day. Mild cases: 250 mg each time, severe cases: 500 mg each time, both once every 12 hours, and the course of treatment is 7 to 14 days. Children over 12 years old should use the adult dose. Children under 12 years old should not use this drug.

1. Nausea, heartburn, abdominal pain, diarrhea, and headache may be seen. Transaminase may increase temporarily, but it can be restored after stopping the drug. There are individual cases of biliary hepatitis. Serious infections caused by fungi or drug-resistant bacteria may occur. In this case, the drug should be stopped and appropriate treatment should be given. Allergic reactions may occur, ranging from drug rash and urticaria in mild cases to allergies in severe cases. There have been reports of transient central nervous system side effects, such as anxiety, dizziness, insomnia, hallucinations, nightmares, and confusion. Adverse reactions include diarrhea (3%), nausea (3%), taste changes (3%), indigestion (2%), abdominal pain or discomfort (2%), and headache (2%), which are generally mild. 2. Increased ALT, AST, LDH, alkaline phosphatase, and bilirubin (all <1%); leukopenia (<1%), and prothrombin

Patients who are allergic to macrolides, pregnant women, breastfeeding women, patients with severe liver and kidney dysfunction, arrhythmia, bradycardia, Q-T interval prolongation, iron deficiency heart disease, congestive heart failure and water and electrolyte disorders should not use this drug or should use it with caution. This drug is mainly metabolized and excreted in the liver, so patients with liver dysfunction, severe renal dysfunction and elderly people over 65 years old should pay special attention to adverse reactions when using this drug. Gastrointestinal dysfunction and systemic symptoms may occur in case of overdose, and gastric lavage and supportive therapy may be given. Neither hemodialysis nor peritoneal dialysis can remove this drug, so the unabsorbed drug should be eliminated as soon as possible (such as gastric lavage) and symptomatic treatment should be given. Pregnant women are prohibited from using this drug (the concentration of this drug in animal embryos is 2-17 times that of human serum). Breastfeeding women should use this drug with caution (breastfeeding should be suspended).

This product can interfere with the metabolism of carbamazepine, causing the latter's blood concentration to increase significantly. When the two are used together, the blood concentration should be monitored and the dosage should be adjusted if necessary. The combination with theophylline can increase the blood concentration of theophylline, but generally there is no need to adjust the dosage of theophylline. This product can change the blood concentration of the following drugs used in combination: digoxin (increase), theophylline (increase), oral anticoagulants (increase), ergotamine or dihydroergot alkaloids (increase), triazolam (increase) and show a stronger effect. For carbamazepine, cyclosporine, hexobarbital, phenytoin, etc., similar metabolic blockade can also be achieved to enhance the effect.

Nanhai Beisha Pharmaceutical Co., Ltd.

• Founded in:

  1993-02-18

• Address:

  No. 21, Shaluo Industrial Zone, Beisha Village, Lishui Town, Nanhai District, Foshan City (Residence declaration)

• Tax NO.:

  91440605280005913Y

• Registered Funds:

  48 million yuan

• Website:

  Log in to view

• Email:

  Log in to view